nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2012 | Original Paper

Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine

verfasst von: Ningning Dong, Jing Yu, Chaoying Wang, Xiaohui Zheng, Zheng Wang, Lijun Di, Guohong Song, Budong Zhu, Li Che, Jun Jia, Hanfang Jiang, Xinna Zhou, Xiaoli Wang, Jun Ren

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC.

Patients and methods

79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ² test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes.

Results

There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004).

Conclusion

CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.

Nur mit Berechtigung zugänglich

Aktas D, Guney I, Alikasifoglu M et al (2002) CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 86:124–128PubMedCrossRef

Bray J, Sludden J, Griffin MJ et al (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102:1003–1009PubMedCrossRef

Canova C, Hashibe M, Simonato L et al (2009) Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res 69:2956–2965PubMedCrossRef

Chan S, Romieu G, Huober J et al (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753–1760PubMedCrossRef

Chen Z, Li Z, Niu X et al (2011) The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis 26:437–446PubMedCrossRef

Cosma G, Crofts F, Taioli E et al (1993) Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40:309–316PubMedCrossRef

Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318PubMedCrossRef

Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12:R26PubMedCrossRef

Harbeck N, Salem M, Nitz U et al (2010) Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev 36:584–594PubMedCrossRef

Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193–200PubMedCrossRef

Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526PubMedCrossRef

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Justenhoven C, Winter S, Hamann U et al (2010) The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors. Cancer 116:5358–5364PubMedCrossRef

Kim HN, Kim NY, Yu L et al (2009) Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma. Am J Hematol 84:821–825PubMedCrossRef

Kiss I, Orsós Z, Gombos K et al (2007) Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 27:2931–2937PubMed

Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287–1293PubMedCrossRef

Ma X, Qi X, Chen C et al (2010) Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls. Breast Cancer Res Treat 122:495–501PubMedCrossRef

Marsh S, Somlo G, Li X et al (2007) Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7:362–365PubMedCrossRef

Mehta R, Jain RK, Badve S (2011) Personalized medicine: the road ahead. Clin Breast Cancer 11:20–26PubMed

Michalaki V, Gennatas S, Gennatas K (2009) Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs 20:204–207PubMedCrossRef

Moreno-Aspitia A, Perez EA (2009) Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31:1619–1640PubMedCrossRef

Murata M, Watanabe M, Yamanaka M et al (2001) Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165:171–177PubMedCrossRef

Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796PubMedCrossRef

O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRef

Petros WP, Hopkins PJ, Spruill S et al (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 23:6117–6125PubMedCrossRef

Ruiter R, Bijl MJ, van Schaik RH et al (2010) CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11:1367–1375PubMedCrossRef

Schroth W, Antoniadou L, Fritz P et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5193PubMedCrossRef

Sergentanis TN, Economopoulos KP (2010) Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:459–469PubMedCrossRef

Taspinar M, Aydos SE, Comez O et al (2008) CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med Wkly 138:12–17PubMed

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24:3747–3755PubMedCrossRef

Tsuchiya Y, Kiyohara C, Sato T et al (2007) Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem 40:881–886PubMedCrossRef

Watson RG, McLeod HL (2011) Pharmacogenomic contribution to drug response. Cancer J 17:80–88PubMedCrossRef

Xu Y, Yao L, Ouyang T et al (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328–7333PubMedCrossRef

Yang J, Qian LX, Wu HF et al (2006) Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: a case-control study in a Han nationality population in Southern China. Int J Urol 13:773–780PubMedCrossRef

Zhuo WL, Zhang YS, Wang Y et al (2009) Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res 40:169–179PubMedCrossRef

Titel: Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
verfasst von: Ningning Dong
Jing Yu
Chaoying Wang
Xiaohui Zheng
Zheng Wang
Lijun Di
Guohong Song
Budong Zhu
Li Che
Jun Jia
Hanfang Jiang
Xinna Zhou
Xiaoli Wang
Jun Ren
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1183-5

Springer Medizin

Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine